Inhibikase Therapeutics to Participate at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced Dr. Milton Werner will participate in a fireside chat at B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on April 28, 2022, at 2:30 PM ET. A live webcast will be available for on-demand viewing on the company's website, with an archival replay accessible for 30 days. The company focuses on developing therapeutics for Parkinson's disease, notably its lead program IkT-148009, aimed at treating the disease both in the brain and gastrointestinal tract.
- None.
- None.
BOSTON and ATLANTA, April 21, 2022 /PRNewswire/ -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinson's disease and related disorders, today announced that Dr. Milton Werner, Ph.D., the Company's President & Chief Executive Officer will participate in a fireside chat at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on April 28, 2022 at 2:30pm ET
A live webcast of the presentation will be available for on-demand viewing under "News & Events" in the Investors section of the Company's website, www.inhibikase.com. An archived replay of the webcast will be available for approximately 30 days. In addition, the Company recently hosted a virtual Key Opinion Leader investor event on April 20, 2022. A replay of the event can be accessed here.
About Inhibikase (www.inhibikase.com)
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Inhibikase's multi-therapeutic pipeline focuses on neurodegeneration and its lead program IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson's disease inside and outside the brain. Its multi-therapeutic pipeline is pursuing Parkinson's-related disorders of the brain and GI tract, orphan indications related to Parkinson's disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent Imatinib that the Company believes will provide a better patient experience with fewer on-dosing side-effects. The Company's RAMP™ medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain. Inhibikase is headquartered in Atlanta, Georgia with offices in Boston, Massachusetts.
Social Media Disclaimer
Investors and others should note that we announce material financial information to our investors using our investor relations website, press releases, SEC filings and public conference calls and webcasts. The Company intends to also use Twitter, Facebook, LinkedIn and YouTube as a means of disclosing information about the Company, its services and other matters and for complying with its disclosure obligations under Regulation FD.
Contacts:
Company Contact:
Milton H. Werner, PhD
President & CEO
678-392-3419
info@inhibikase.com
Investor Relations:
Alex Lobo
SternIR, Inc.
alex.lobo@sternir.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inhibikase-therapeutics-to-participate-at-the-b-riley-securities-2022-virtual-neuro--ophthalmology-conference-301530237.html
SOURCE Inhibikase Therapeutics, Inc.
FAQ
What is the date and time of Inhibikase's participation in the B. Riley Securities conference?
How can I access the live webcast of Inhibikase's presentation?
What is the focus of Inhibikase Therapeutics?
What is the lead program of Inhibikase Therapeutics?
Will there be a replay available after the conference?
